LIFECODE BIOTECH LIMITED COMPANY
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
1. Circulating Tumor Cell (CTC) Detection Services: Non-invasive early cancer screening and recurrence monitoring, providing additional cancer risk indicators and information.
2. Genetic Testing Services: To understand the status of tumor gene mutations in cancer tissues, gain a deeper understanding of the causes of cancer development and the correlation between cancer progression and genes, thereby assisting physicians in formulating appropriate treatment strategies.
3. Development of Research Projects for Clinical Application: Translating research findings into clinical applications through the development of cutting-edge research projects and the design of microfluidic chip instruments.
(The content above was translated by AI.)
2. Genetic Testing Services: To understand the status of tumor gene mutations in cancer tissues, gain a deeper understanding of the causes of cancer development and the correlation between cancer progression and genes, thereby assisting physicians in formulating appropriate treatment strategies.
3. Development of Research Projects for Clinical Application: Translating research findings into clinical applications through the development of cutting-edge research projects and the design of microfluidic chip instruments.
(The content above was translated by AI.)
Founded Year
2017
Unified Business No.
52615491
Status
Active
Number of Employees
0
Total Paid-in
Capital
85,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
LIFECODE BIOTECH LIMITED COMPANY, established in 2017, is a biotechnology company engaged in precision medicine. The company's founder is an internationally renowned expert in molecular diagnostics who has served as a professor at the University of Maryland School of Medicine and the Institute of Biotechnology. He has also worked as a researcher at institutions such as the Massachusetts Institute of Technology, Harvard University, the University of Chicago Medicine, and the National Institutes of Health – National Cancer Institute in the United States. Other members of the company include experts in various fields such as liquid biopsy, cancer genomics, tumor and cell biology, bioinformatics, and clinical medicine.
In addition to providing genetic testing services, LIFECODE BIOTECH LIMITED COMPANY actively engages in industry-academia collaboration with well-known domestic medical centers, aiming to apply research findings to clinical practice by developing cutting-edge research projects, such as next-generation DNA sequencing (NGS) and liquid biopsy technologies. For the prevention, diagnosis, and treatment of diseases, especially the early detection, recurrence, and monitoring of cancer, the company can provide constructive and meaningful personalized medical solutions to further achieve precise cancer treatment.
(The content above was translated by AI.)
In addition to providing genetic testing services, LIFECODE BIOTECH LIMITED COMPANY actively engages in industry-academia collaboration with well-known domestic medical centers, aiming to apply research findings to clinical practice by developing cutting-edge research projects, such as next-generation DNA sequencing (NGS) and liquid biopsy technologies. For the prevention, diagnosis, and treatment of diseases, especially the early detection, recurrence, and monitoring of cancer, the company can provide constructive and meaningful personalized medical solutions to further achieve precise cancer treatment.
(The content above was translated by AI.)
